Stock Insider Ownership (from SEC Form 4)

RDUS / Radius Health, Inc. insiders include MPM Bio IV NVS Strategic Fund LP, MPM BioVentures IV LLC, MPM BIOVENTURES III LLC, MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC, MPM BIOVENTURES III GP L.P., GALAKATOS NICHOLAS, Carmona Jose (Chief Financial Officer), EVNIN LUKE, Fitzpatrick Lorraine A. (Chief Medical Officer), BIOTECH GROWTH N V MPM BIOVENTURES III GMBH & CO. Beteiligungs KG, MPM BIOVENTURES III-QP L.P., Ward Robert (President & CEO), MPM BIOVENTURES III PARALLEL FUND, L.P., Scopa James Paul, Foley Todd, Purandare Dinesh (SVP Global Oncology/Commercial), STEINMETZ MICHAEL, GADICKE ANSBERT, Hattersley Gary (Chief Scientific Officer), KAILIAN VAUGHN M, BB BIOTECH AG, and MPM BIOVENTURES III L.P., SIMON NICHOLAS J III, MPM BioVentures IV GP LLC, HENNER DENNIS, Hoiland Jesper (President and CEO), Harvey Brian Nicholas (Sr. VP and CFO), Snow David P. (Chief Commercial Officer), Graves Kurt, WHEELER KURT, .


Radius Health, Inc. insider trades are found here. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

Job titles are listed as of the filing and may not be current. Click the link icon to see the full transaction history.

Latest
Tran Date
Insider Code Shares Post Shares Percent
Change
Share
Price
Tran Value Post Value Percent
Change
2017-09-14 BIOTECH GROWTH N V 10% Owner
BB BIOTECH AG 10% Owner
P 50,000 5,498,799 0.92 32.9445 1,647,225 181,155,184 0.91
2017-09-14 Carmona Jose Chief Financial Officer
P 3,000 3,000 32.8343 98,503 98,503 100.00
2017-09-15 Hoiland Jesper President and CEO Director
P 6,100 6,100 32.7227 199,608 199,608 100.00
2017-04-25 Harvey Brian Nicholas Sr. VP and CFO
M 39,616 76,189 108.32 2.74 108,548
2016-10-25 Ward Robert President & CEO Director
M 10,000 15,000 200.00 7.8 78,000
2016-09-27 MPM BioVentures IV LLC
Scopa James Paul
MPM BioVentures IV GP LLC
MPM Bio IV NVS Strategic Fund LP
KAILIAN VAUGHN M
Foley Todd
J -713,849 1,427,698 -33.33
2016-09-27 EVNIN LUKE
J -1,943,751 3,887,502 -33.33
2016-09-27 GADICKE ANSBERT Director
J -1,943,751 3,887,502 -33.33
2016-09-27 GALAKATOS NICHOLAS
SIMON NICHOLAS J III
WHEELER KURT
J -1,229,902 2,459,804 -33.33
2016-09-27 MPM BIOVENTURES III LLC
HENNER DENNIS
MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC
MPM BIOVENTURES III GMBH & CO. Beteiligungs KG
MPM BIOVENTURES III PARALLEL FUND, L.P.
MPM BIOVENTURES III GP L.P.
MPM BIOVENTURES III L.P.
MPM BIOVENTURES III-QP L.P.
STEINMETZ MICHAEL
J -1,229,902 2,459,804 -33.33
2016-01-25 Fitzpatrick Lorraine A. Chief Medical Officer
P 100 200 100.00 37.97 3,797 7,594 50.00
2015-11-12 Hattersley Gary Chief Scientific Officer
S -5,683 0 -100.00 75.00 -426,225
2015-09-14 Snow David P. Chief Commercial Officer
P 6,000 6,000 69.79 418,740 418,740 100.00
2015-08-31 Purandare Dinesh SVP Global Oncology/Commercial
P 200 200 62.20 12,440 12,440 100.00
2015-08-17 Graves Kurt Director
S -22,694 0 -100.00 70.00 -1,588,580
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related News Stories

Radius (RDUS) Enrols First Patient in Breast Cancer Study

2017-10-02 zacks
Radius Health, Inc. (RDUS - Free Report) announced that the first patient has been enroled in the phase I study on pipeline candidate, RAD140. (103-1)

Biotech Forum Daily Digest: Revisiting Radius Health

2017-09-14 seekingalpha
The main biotech indices are down slightly on the week in listless trading as the sector consolidates recent gains. (7-2)

Radius Health (RDUS) Presents at Morgan Stanley 15th Annual Global Healthcare Conference (Transcript)

2017-09-13 seekingalpha
We’re going to get started with the next session, which is Radius. Quickly, before we get started, I just need to read a quick disclosure statement. Please note that all important disclosures including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up a copy at the registration desk. (1-0)

BRIEF-Radius Health prices $300 mln of 3 pct convertible senior notes due 2024

2017-08-09 reuters
* Radius Health announces pricing of $300 million of 3.00 percent convertible senior notes due 2024

Radius (RDUS) Q2 Loss Wider than Expected on Higher Expenses

2017-08-04 zacks
Radius Health, Inc. (RDUS - Free Report) posted a loss of $1.58 per share in the second quarter of 2017, wider than the loss of $1.01 per share in the year-ago quarter and wider than the Zacks Consensus Estimate loss of $1.35. The year-over-year increase in net loss was attributable to an increase in general and administrative expenses.

Radius Health's (RDUS) CEO Jesper Høiland on Q2 2017 Results - Earnings Call Transcript

2017-08-04 seekingalpha
Good afternoon everyone and welcome to Radius Health's Second Quarter 2017 Results and Business Update. Today’s call is being recorded.

Radius Health, Inc. 2017 Q2 - Results - Earnings Call Slides

2017-08-04 seekingalpha
The following slide deck was published by Radius Health, Inc. in conjunction with their 2017 Q2 earnings call.